In 2022, Zhao and co-workers adopted this approach by designing new coumarin derivatives that were tested against multiple targets relevant for AD, such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), glycogen synthase kinase-3 beta (GSK-3β) and Beta-secretase 1 (BACE1) (Liu et al., 2022). This evidence concerns the gene ACHE and Alzheimer disease.